A triple-receptor (GIP/GLP-1/glucagon) agonist compound, currently in pharmaceutical clinical development, sold in the research-chemical retail market as a raw/compounded article. The Peptide Index files it under GIP/GLP-1/glucagon triple receptor agonist. Vendors also list it as “Reta”.
As of Sep 25, 2026, the lowest listed price is $2.99/mg and the median current listing is $8.17/mg, across 76 vendors (256 comparable single-compound listings). Prices are normalized to US dollars per milligram of peptide, exclude shipping, and are refreshed nightly.
In the nightly price history, the daily median rose from $5.58/mg on Jul 14, 2026 to $8.70/mg on Sep 25, 2026 (+55.8%), based on 67 observed days. Days the crawl missed are left out, not filled in. The daily series is taken across each day’s comparable listings, so it can differ slightly from the current-listings median above. See the full Retatrutide price history chart.
| Vendor | $/mg | Price (USD) | Package |
|---|---|---|---|
| Labrat Peptides | $2.99/mg | $299.00 | 100mg vial |
| My GLP-1 Store | $3.10/mg | $149.00 | 48mg vial |
| Peptide Partners | $3.15/mg | $1512.00 | 480mg vial |
| Bulk GLP | $3.56/mg | $1780.00 | 500mg vial |
| Alpha Peptides | $3.60/mg | $107.99 | 30mg vial |
Each vendor name links to its public-record trust profile. The Retatrutide price page lists every current listing.
Every night The Peptide Index reads vendors’ public catalog pages, records the listed price and stated peptide content, and divides one by the other to get a comparable $/mg. Blends and topical/cosmetic products are excluded from single-compound figures. Read the full methodology and how vendor signals are checked.